An update clinical application of amniotic fluid-derived stem cells (AFSCs) in cancer cell therapy and tissue engineering

Abstract

Recent studies have elucidated that cell-based therapies are promising for cancer treatments. The human amniotic fluid stem (AFS) cells are advantageous cells for such therapeutic schemes that can be innately changed to express therapeutic proteins. HAFSCs display a natural tropism to cancer cells in vivo. They can be useful in cancer cells targeting. Moreover, they are easily available from surplus diagnostic samples during pregnancy and less ethical and legal concern are associated with the collection and application than other putative cells are subjected. This review will designate representatives of amniotic fluid and stem cell derived from amniotic fluid. For this propose, we collect state of human AFS cells data applicable in cancer therapy by dividing this approach into two main classes (nonengineered and engineered based approaches). Our study shows the advantage of AFS cells over other putative cells types in terms differentiation ability to a wide range of cells by potential and effective use in preclinical studies for a variety of diseases. This study has shown the elasticity of human AFS cells and their favorable potential as a multipotent cell source for regenerative stem cell therapy and capable of giving rise to multiple lineages including such as osteoblasts and adipocyte.

Keywords:

• Human amniotic fluid stem (hAFS) cells
• cell-based therapies
• cancer cells targeting
• cancer therapy

Acknowledgements

The authors thank the Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Science and Women’s Reproductive Health Research Center Al-Zahra Hospital, Tabriz University of Medical Sciences for all support provided (Study ID: 93/4-10/2).

Disclosure statement

The authors declare no conflicts of interest. The authors alone are responsible for the content and writing of the manuscript.